Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bausch + Lomb Corporation Common Shares
(NY:
BLCO
)
19.97
-0.04 (-0.18%)
Delayed Quote
Updated: 11:31 AM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bausch + Lomb Corporation Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
1 cash-producing stock on our buy list and 2 that underwhelm
October 30, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education
October 29, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call
↗
October 29, 2026
Bausch + Lomb (NYSE:BLCO) reported third-quarter revenue growth across all three business segments, raised its full-year outlook for the third time in 2026 and highlighted continued margin expansion...
Via
MarketBeat
Topics
Earnings
Bausch + Lomb (BLCO) stock trades up, here is why
October 28, 2026
What happened? Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 8.7% in the afternoon session after the company reported third-quarter 2026 revenue...
Via
StockStory
Topics
Artificial Intelligence
Economy
Initial Public Offering
Bausch + Lomb (BLCO) Q3 2026 Earnings Call Transcript
↗
October 28, 2026
Dry eye drugs and premium surgical lenses drove broad-based growth across all segments.
Via
The Motley Fool
Topics
Earnings
World Trade
Bausch + Lomb (NYSE:BLCO) posts Q3 2026 profit well ahead of estimates
October 28, 2026
Eyecare company Bausch + Lomb (NYSE:BLCO) exceeded Wall Street’s revenue expectations in Q3 2026, with revenue up 7.3% year on year to $1.38 billion. The com...
Via
StockStory
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
October 28, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
Bausch + Lomb (BLCO) reports Q3: everything you need to know ahead of earnings
October 26, 2026
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market open. Here’s what to expect. Bausch + Lomb beat analysts’ re...
Via
StockStory
3 Reasons BLCO is Risky and 1 Stock to Buy Instead
October 16, 2026
Bausch + Lomb currently trades at $16.69 per share and has shown little upside over the past six months, posting a middling return of 0.6%. The stock also fe...
Via
StockStory
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
October 12, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
3 Low-Volatility Stocks with Open Questions
October 08, 2026
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...
Via
StockStory
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
October 06, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
October 05, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
3 Small-Cap Stocks That Concern Us
September 17, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Via
StockStory
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
September 11, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
September 09, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
September 02, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
September 01, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
August 28, 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via
StockStory
3 Healthcare Stocks We Steer Clear Of
August 27, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...
Via
StockStory
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential
↗
August 25, 2026
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.
Via
Benzinga
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack
August 24, 2026
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty...
Via
StockStory
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
↗
August 24, 2026
Bausch + Lomb (NYSE:BLCO) said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at...
Via
MarketBeat
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
August 24, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
3 Stocks Under $50 We’re Skeptical Of
August 18, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via
StockStory
Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000
↗
August 13, 2026
Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following a 23% stock gain over 12 months.
Via
The Motley Fool
Topics
Regulatory Compliance
Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Revenue grew 8% while EBITDA surged 28%, driven by dry eye and surgical strength.
Via
The Motley Fool
Topics
Earnings
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
August 06, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
Bausch + Lomb Q2 Earnings Call Highlights
↗
July 29, 2026
Bausch + Lomb (NYSE:BLCO) reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook....
Via
MarketBeat
Topics
Earnings
Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations
July 29, 2026
Eyecare company Bausch + Lomb (NYSE:BLCO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $1.39 bil...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
